338 related articles for article (PubMed ID: 11966452)
1. Comparative evaluation of L-Fd4C and related nucleoside analogs as promising antiviral agents.
Chen SH
Curr Med Chem; 2002 May; 9(9):899-912. PubMed ID: 11966452
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the antiviral effect of 2',3'-dideoxy-2', 3'-didehydro-beta-L-5-fluorocytidine in the duck hepatitis B virus infection model.
Le Guerhier F; Pichoud C; Guerret S; Chevallier M; Jamard C; Hantz O; Li XY; Chen SH; King I; Trépo C; Cheng YC; Zoulim F
Antimicrob Agents Chemother; 2000 Jan; 44(1):111-22. PubMed ID: 10602731
[TBL] [Abstract][Full Text] [Related]
3. Anti-hepatitis B virus activity and metabolism of 2',3'-dideoxy-2',3'-didehydro-beta-L(-)-5-fluorocytidine.
Zhu YL; Dutschman DE; Liu SH; Bridges EG; Cheng YC
Antimicrob Agents Chemother; 1998 Jul; 42(7):1805-10. PubMed ID: 9661025
[TBL] [Abstract][Full Text] [Related]
4. Antiviral activity of beta-L-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine in woodchucks chronically infected with woodchuck hepatitis virus.
Le Guerhier F; Pichoud C; Jamard C; Guerret S; Chevallier M; Peyrol S; Hantz O; King I; Trépo C; Cheng YC; Zoulim F
Antimicrob Agents Chemother; 2001 Apr; 45(4):1065-77. PubMed ID: 11257017
[TBL] [Abstract][Full Text] [Related]
5. Animal models for the study of HBV infection and the evaluation of new anti-HBV strategies.
Zoulim F; Berthillon P; Guerhier FL; Seigneres B; Germon S; Pichoud C; Cheng YC; Trepo C
J Gastroenterol Hepatol; 2002 Dec; 17 Suppl():S460-3. PubMed ID: 12534778
[TBL] [Abstract][Full Text] [Related]
6. Characterization of hepatitis B virus inhibition by novel 2'-fluoro-2',3'-unsaturated beta-D- and L-nucleosides.
Pai SB; Pai RB; Xie MY; Beker T; Shi J; Tharnish PM; Chu CK; Schinazi RF
Antivir Chem Chemother; 2005; 16(3):183-92. PubMed ID: 16004081
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of 2',3'-dideoxy-L-pyrimidine nucleosides as potential antiviral agents against human immunodeficiency virus (HIV) and hepatitis B virus (HBV).
Lin TS; Luo MZ; Liu MC; Pai SB; Dutschman GE; Cheng YC
J Med Chem; 1994 Mar; 37(6):798-803. PubMed ID: 8145230
[TBL] [Abstract][Full Text] [Related]
8. Metabolism of 2',3'-dideoxy-2',3'-didehydro-beta-L(-)-5-fluorocytidine and its activity in combination with clinically approved anti-human immunodeficiency virus beta-D(+) nucleoside analogs in vitro.
Dutschman GE; Bridges EG; Liu SH; Gullen E; Guo X; Kukhanova M; Cheng YC
Antimicrob Agents Chemother; 1998 Jul; 42(7):1799-804. PubMed ID: 9661024
[TBL] [Abstract][Full Text] [Related]
9. Effect of beta-enantiomeric and racemic nucleoside analogues on mitochondrial functions in HepG2 cells. Implications for predicting drug hepatotoxicity.
Cui L; Schinazi RF; Gosselin G; Imbach JL; Chu CK; Rando RF; Revankar GR; Sommadossi JP
Biochem Pharmacol; 1996 Nov; 52(10):1577-84. PubMed ID: 8937473
[TBL] [Abstract][Full Text] [Related]
10. Strong antiviral activity of the new l-hydroxycytidine derivative, l-Hyd4FC, in HBV-infected human chimeric uPA/SCID mice.
Volz T; Lütgehetmann M; Allweiss L; Warlich M; Bierwolf J; Pollok JM; Petersen J; Matthes E; Dandri M
Antivir Ther; 2012; 17(4):623-31. PubMed ID: 22368233
[TBL] [Abstract][Full Text] [Related]
11. Phosphatidyl-2',3'-dideoxy-3'-thiacytidine: synthesis and antiviral activity in hepatitis B-and HIV-1-infected cells.
Xie H; Voronkov M; Liotta DC; Korba BA; Schinazi RF; Richman DD; Hostetler KY
Antiviral Res; 1995 Oct; 28(2):113-20. PubMed ID: 8585765
[TBL] [Abstract][Full Text] [Related]
12. Antiviral activity of 2',3'-dideoxy-beta-L-5-fluorocytidine (beta-L-FddC) and 2',3'-dideoxy-beta-L-cytidine (beta-L-ddC) against hepatitis B virus and human immunodeficiency virus type 1 in vitro.
Lin TS; Luo MZ; Liu MC; Pai SB; Dutschman GE; Cheng YC
Biochem Pharmacol; 1994 Jan; 47(2):171-4. PubMed ID: 8304960
[TBL] [Abstract][Full Text] [Related]
13. Nucleoside analogs as anti-HBV agents.
Zhou XX; Littler E
Curr Top Med Chem; 2006; 6(9):851-65. PubMed ID: 16787280
[TBL] [Abstract][Full Text] [Related]
14. Clinical potential of emerging new agents in hepatitis B.
Farrell GC
Drugs; 2000 Oct; 60(4):701-10. PubMed ID: 11085196
[TBL] [Abstract][Full Text] [Related]
15. Perspectives for the treatment of hepatitis B virus infections.
De Clercq E
Int J Antimicrob Agents; 1999 Jul; 12(2):81-95. PubMed ID: 10418752
[TBL] [Abstract][Full Text] [Related]
16. Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation.
Delaney WE; Locarnini S; Shaw T
Antivir Chem Chemother; 2001 Jan; 12(1):1-35. PubMed ID: 11437320
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of 2',3'-dideoxy-2',3'-didehydro-beta-L-cytidine (beta-L-d4C) and 2',3'-dideoxy 2',3'-didehydro-beta-L-5-fluorocytidine (beta-L-Fd4C), two exceptionally potent inhibitors of human hepatitis B virus (HBV) and potent inhibitors of human immunodeficiency virus (HIV) in vitro.
Lin TS; Luo MZ; Liu MC; Zhu YL; Gullen E; Dutschman GE; Cheng YC
J Med Chem; 1996 Apr; 39(9):1757-9. PubMed ID: 8627596
[No Abstract] [Full Text] [Related]
18. Bis-S-acyl-2-thioethyl (SATE)-bearing monophosphate prodrug of beta-L-FD4C as potent anti-HBV agent.
Li X; Carmichael E; Feng M; King I; Doyle TW; Chen SH
Bioorg Med Chem Lett; 1998 Jan; 8(1):57-62. PubMed ID: 9871628
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of 4-substituted fluoronucleoside analogs for the treatment of hepatitis B virus infection.
Yang Q; Kang J; Zheng L; Wang XJ; Wan N; Wu J; Qiao Y; Niu P; Wang SQ; Peng Y; Wang Q; Yu W; Chang J
J Med Chem; 2015 May; 58(9):3693-703. PubMed ID: 25905540
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and comparative evaluation of two antiviral agents: beta-L-Fd4C and beta-D-Fd4C.
Chen SH; Lin S; King I; Spinka T; Dutschman GE; Gullen EA; Cheng YC; Doyle TW
Bioorg Med Chem Lett; 1998 Nov; 8(22):3245-50. PubMed ID: 9873711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
